Table 2.
Patient and control participant characteristics.
Categorical variable | Healthy (n = 30) |
Vasculitis (n = 52) |
Fibromyalgia (n = 30) |
p-value |
---|---|---|---|---|
Number (percentage) | Number (percentage) | Number (percentage) | ||
Sex (F) | 20/30 (66.7) | 30/52 (57.6) | 30/30 (100) | <0.001 |
Marital status | ||||
Single | 4/29 (13.7) | 9/50 (18.0) | 0/30 (0.0) | |
Married | 23/29 (79.3) | 33/50 (66.0) | 25/30 (83.3) | |
Separated/divorced | 2/29 (6.8) | 4/50 (8.0) | 5/30 (16.6) | |
Widowed | 0/29 (0.0) | 4/50 (8.0) | 0/30 (0.0) | 0.05 |
Education | ||||
<High school | 3/28 (10.7) | 2/47 (4.2) | 0/26 (0.0) | |
High school | 5/28 (17.8) | 15/47 (31.9) | 7/26 (26.9) | |
Graduate degree | 13/28 (46.4) | 20/47 (42.5) | 15/26 (57.6) | |
Professional degree | 7/28 (25.0) | 10/47 (21.2) | 4/26 (15.3) | 0.43 |
Employment | ||||
Disability | 0/28 (0.0) | 5/50 (10.0) | 1/29 (3.4) | |
Student | 2/28 (7.1) | 1/50 (2.0) | 0/29 (0.0) | |
Homemaker | 1/28 (3.5) | 0/50 (0.0) | 2/29 (6.8) | |
Retired | 1/28 (3.5) | 17/50 (34.0) | 2/29 (6.8) | |
Unemployed | 2/28 (7.1) | 1/50 (2.0) | 3/29 (10.3) | |
Employed | 22/28 (78.5) | 26/50 (52.0) | 21/29 (72.4) | 0.004 |
ME/CFS | ||||
Noa | 24/30 (80.0) | 18/52 (34.6) | 0/30 (0.0) | |
Atypicalb | 6/30 (20.0) | 7/52 (13.4) | 0/30 (0.0) | |
Yesc | 0/30 (0.0) | 27/52 (51.9) | 30/30 (100) | <0.001 |
Fibromyalgia (Y) | 0/30 (0.0) | 10/52 (19.2) | 30/30 (100) | <0.001 |
Continuous variables | Mean (SD) | Mean (SD) | Mean (SD) | |
Age (yrs) | 44.7 (12.6) | 53.3 (15.8) | 44.3 (9.9) | 0.02 |
BMI (kg/m2) | 27.4 (6.2) | 29.0 (5.6) | 26.6 (6.9) | 0.30 |
CRP | 3.4 (4.3) | 6.3 (10.2) | 4.2 (4.6) | <0.001 |
Significant p values are indicated in bold.
Y-Yes; F-Female; ME/CFS-Myalgic encephalomyelitis/chronic fatigue syndrome; BMI-Body mass index; CRP-C reactive protein.
No fatigue, defined as 0–2 criteria based on the Canadian consensus criteria.
Atypical, defined as 3–4 criteria based on the Canadian consensus criteria.
ME/CFS, defined as 5–6 criteria based on the Canadian consensus criteria.